COVID-19 and Sirolimus Treatment in a Kidney Transplant Recipient.
Exp Clin Transplant
; 19(9): 977-980, 2021 09.
Article
in English
| MEDLINE | ID: covidwho-1404031
ABSTRACT
One year after COVID-19 was declared a pandemic, the management of the disease in kidney transplant patients remains uncertain. The interruption of immunosuppressive therapy is frequently suggested in kidney transplant recipients with COVID-19; however, such an interruption potentially increases the risk of allograft rejection and hyperimmune response. We here report the successful treatment of COVID-19 pneumonia in a kidney transplant recipient who received a sirolimus-based regimen. The course of COVID-19 management was favorable for maintaining sirolimus treatment. Nevertheless, the patient showed signs of extreme overexposure to sirolimus because of drug interaction with antiviral treatment. This case illustrates the advantages and related adverse events of sirolimus-based immunosuppression in the management of COVID-19 in kidney transplant recipients.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Kidney Transplantation
/
Sirolimus
/
COVID-19
Type of study:
Case report
/
Prognostic study
Limits:
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Exp Clin Transplant
Journal subject:
Transplantation
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS